Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

VYNE Therapeutics (VYNE) Profit After Tax (2016 - 2025)

VYNE Therapeutics (VYNE) has disclosed Profit After Tax for 10 consecutive years, with -$5.8 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Profit After Tax rose 38.75% year-over-year to -$5.8 million, compared with a TTM value of -$38.5 million through Jun 2025, down 35.46%, and an annual FY2025 reading of -$26.5 million, up 33.43% over the prior year.
  • Profit After Tax was -$5.8 million for Q2 2025 at VYNE Therapeutics, up from -$8.6 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $17.6 million in Q4 2021 and bottomed at -$21.6 million in Q2 2022.
  • Average Profit After Tax over 5 years is -$8.9 million, with a median of -$8.9 million recorded in 2022.
  • The sharpest move saw Profit After Tax skyrocketed 175.71% in 2021, then plummeted 220.39% in 2023.
  • Year by year, Profit After Tax stood at $17.6 million in 2021, then tumbled by 144.22% to -$7.8 million in 2022, then grew by 13.26% to -$6.7 million in 2023, then tumbled by 78.46% to -$12.0 million in 2024, then soared by 52.14% to -$5.8 million in 2025.
  • Business Quant data shows Profit After Tax for VYNE at -$5.8 million in Q2 2025, -$8.6 million in Q1 2025, and -$12.0 million in Q4 2024.